---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-016486"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2026-04-14T23:59:59+00:00"
generated_at: "2026-05-15T06:23:58.871950+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CyPath® Lung case study shows test helped defer biopsy for high-risk patient with 30mm nodule

## Summary
- 70-year-old female, 50 pack-year smoking history, 30mm lung nodule with high cancer risk by imaging and models.
- CyPath® Lung returned negative result ('Unlikely Malignancy'); follow-up CT showed nodule had completely resolved.
- Treating pulmonologist credited CyPath® Lung for prompting additional imaging before scheduled biopsy.
- CyPath® Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in small nodules in clinical trial.
- Case illustrates potential to avoid risky, unnecessary procedures in patients with comorbidities like emphysema.

## SEC filing metadata
- accession: 0001493152-26-016486
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2026-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315226016486/0001493152-26-016486-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315226016486/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-016486
- JSON: https://secwatch.observer/filing/0001493152-26-016486.json
- Plain text: https://secwatch.observer/filing/0001493152-26-016486.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.